Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-25-001669

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Mar 7, 2025 6.86M sh
Cash And Equivalents Q3 2025 · Jan 31, 2025 $16.38M
Cash And Equivalents Q3 2025 · Apr 30, 2024 $50.18M
Current Liabilities Q3 2025 · Jan 31, 2025 $1.19M
Current Liabilities Q3 2025 · Apr 30, 2024 $7.42M
Total Liabilities Q3 2025 · Jan 31, 2025 $3.58M
Total Liabilities Q3 2025 · Apr 30, 2024 $20.39M
Current Assets Q3 2025 · Jan 31, 2025 $16.96M
Current Assets Q3 2025 · Apr 30, 2024 $50.44M
Total Assets Q3 2025 · Jan 31, 2025 $43.83M
Total Assets Q3 2025 · Apr 30, 2024 $59.9M
Shares Diluted Q3 2025 · Jan 31, 2024 8.61M sh
Shares Diluted Q3 2025 · Jan 31, 2024 9.99M sh
Stock Repurchased Q3 2025 · Jan 31, 2024 $27.02M
Operating Cash Flow Q3 2025 · Jan 31, 2024 −$1.82M
Stockholders Equity Q3 2025 · Jan 31, 2024 $31.37M
Stockholders Equity Q3 2025 · Oct 31, 2023 $36.77M
Stockholders Equity Q3 2025 · Jul 31, 2023 $39.19M
Stockholders Equity Q3 2025 · Apr 30, 2023 $72.69M
Eps Diluted Q3 2025 · Jan 31, 2024 −$0.65
Eps Diluted Q3 2025 · Jan 31, 2024 −$1.47
Eps Basic Q3 2025 · Jan 31, 2024 −$0.65
Eps Basic Q3 2025 · Jan 31, 2024 −$1.47
Rd Expense Q3 2025 · Jan 31, 2024 $126.73K
Rd Expense Q3 2025 · Jan 31, 2024 $313.25K
Net Income Q3 2025 · Jan 31, 2024 −$619.54K
Net Income Q3 2025 · Jan 31, 2024 −$1.01M
Net Income Q3 2025 · Oct 31, 2023 $2.79M
Net Income Q3 2025 · Jul 31, 2023 −$3.18M
Operating Income Q3 2025 · Jan 31, 2024 −$1.87M
Operating Income Q3 2025 · Jan 31, 2024 −$5.35M
Revenue Q3 2025 · Jan 31, 2024 $0
Revenue Q3 2025 · Jan 31, 2024 $0